OpenAI launched its dedicated ChatGPT Health feature on January 8, 2026, aiming to provide users with a new way to understand their health information and prepare for medical consultations, but its rollout across Europe faces potential hurdles regarding clinical validation and regulatory compliance.
The new feature is designed to securely connect users’ health data and applications, offering a physician-informed approach to health insights. OpenAI emphasizes that ChatGPT Health is intended to augment, not replace, the role of medical professionals. According to OpenAI, the tool is designed to help individuals identify patterns in their health data and formulate questions for their doctors.
However, experts are raising concerns about the feature’s readiness for deployment in highly regulated markets like the European Economic Area, the UK, and Switzerland. A key issue centers on the necessitate for rigorous clinical validation to ensure the accuracy and reliability of the AI-driven health advice. Recent assessments, including a 2025 Medscape report, showed that while patients rated ChatGPT’s responses to health questions as comparable to those from specialist surgeons, the AI likewise demonstrated a propensity for “hallucinations” – generating incorrect or misleading information.
The potential for these inaccuracies raises significant liability concerns. The Medscape report highlighted the legal risks associated with relying on AI-driven medical advice, particularly in cases where incorrect information leads to adverse health outcomes. These concerns are amplified by the stringent regulatory frameworks governing healthcare in Europe, which prioritize patient safety and data privacy.
OpenAI has stated that ChatGPT Health incorporates privacy protections, but the specifics of these safeguards and their compliance with regulations like the General Data Protection Regulation (GDPR) remain under scrutiny. The company has not yet detailed how it will address the clinical validation requirements necessary for approval in the EEA, UK, and Switzerland.
The launch of ChatGPT Health comes as OpenAI prepares to tap into users’ broader health information, according to reports. This expansion of data access further intensifies the need for robust security measures and regulatory oversight. As of February 16, 2026, OpenAI has not announced a firm timeline for the availability of ChatGPT Health in the aforementioned regions, citing the need to address these regulatory considerations.
